Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study.

Suresh S. Ramalingam Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA info_outline Suresh S. Ramalingam, Terufumi Kato, Xiaorong Dong, Myung-Ju Ahn, Le-Van Quang, Nopadol Soparattanapaisarn, Takako Inoue, Chih-Liang Wang, Meijuan Huang, James Chih-Hsin Yang, Manuel Cobo, Mustafa Özgüroğlu, Ignacio Casarini, Dang-Van Khiem, Virote Sriuranpong, Eduardo Cronemberger, Xiangning Huang, Toon van der Gronde, Dana C. Ghiorghiu, Shun Lu

Authors Suresh S. Ramalingam Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA info_outline Suresh S. Ramalingam, Terufumi Kato, Xiaorong Dong, Myung-Ju Ahn, Le-Van Quang, Nopadol Soparattanapaisarn, Takako Inoue, Chih-Liang Wang, Meijuan Huang, James Chih-Hsin Yang, Manuel Cobo, Mustafa Özgüroğlu, Ignacio Casarini, Dang-Van Khiem, Virote Sriuranpong, Eduardo Cronemberger, Xiangning Huang, Toon van der Gronde, Dana C. Ghiorghiu, Shun Lu Organizations Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA, Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, Department of Oncology, Hanoi Medical University, Hanoi, Viet Nam, Mahidol University, Sriraj Hospital, Bangkok, Thailand, Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan, Division of Pulmonary Oncology and Interventional Bronchoscopy, Department of Thoracic Medicine, Linkou Chang Gung Memorial Hospital, Medical College of Chang Gung University, Taoyuan, Taiwan, Division of Thoracic Tumor Multimodality Treatment and Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China, Department of Oncology, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan, Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain, Department of Internal Medicine, Division of Medical Oncology, Clinical Trial Unit, Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Istanbul, Turkey, Servicio Oncología, Hospital Bernardo Houssay, Mar del Plata, Buenos Aires, Argentina, Vietnam National Lung Hospital, Hanoi, Viet Nam, Division of Medical Oncology, Faculty of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand, Centro de Pesquisa Clínica CRIO, Centro Regional Integrado de Oncologia, Fortaleza, Ceará, Brazil, Biometrics, Late-stage Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom, Late-stage Development, Oncology R&D, AstraZeneca, New York, NY, Late-stage Development, Oncology R&D, AstraZeneca, Baar, Switzerland, Department of Medical Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China Abstract Disclosures

Clinical